Xenon Pharma Partners with Merck & Co.

Xenon Pharmaceuticals of Vancouver has signed a strategic partnership with Merck & Co., related to novel small molecule candidates for the potential treatment of cardiovascular disease. Under terms of the agreement, Xenon receives research funding and is eligible for up to $94.5 million for the first target and up to $89.5 million for subsequent targets. Xenon previously raised over $90 million from firms like Invesco, Roche and Takeda Research Investment.